Skip to main content
Retour
GLUE logo

Monte Rosa Therapeutics, Inc.

Qualité des données : 100%
Survendu
GLUE
NASDAQ Healthcare Biotechnology
14,72 €
▼ 0,31 € (-2,06%)
Cap. Boursière : 958,61M
Fourchette du Jour
14,20 € 14,92 €
Fourchette 52 Semaines
3,50 € 25,77 €
Volume
1 627 964
Moyenne 50J / 200J
19,78 € / 11,73 €
Clôture Précédente
15,03 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -24,8 0,3
P/B 4,1 2,9
ROE % -16,9 3,7
Net Margin % -31,2 3,8
Rev Growth 5Y % 10,0
D/E 0,2 0,2

Objectif de Cours des Analystes

Hold
31,75 € +115.7%
Low: 22,00 € High: 37,00 €
BPA Prévisionnel
-1,52 €
CA Est.
57 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 -1,60 €
-4,15 € – -0,19 €
170 M 1
FY2029 -2,13 €
-5,51 € – -0,25 €
120 M 1
FY2028 -2,26 €
-2,90 € – -1,47 €
38 M 5

Points Clés

Debt/Equity of 0,17 — conservative balance sheet
Negative free cash flow of -27,50M
PEG of 0,64 suggests growth is underpriced
Capital efficient — spends only 3,80% of revenue on capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)63,54%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-16,94%
ROIC-14,93%
Net Margin-31,23%
Op. Margin-43,83%

Sécurité

Debt / Equity
0,17
Current Ratio6,12
Interest Coverage0,00

Valorisation

P/E Ratio
-24,82
P/B Ratio4,11
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 63,54% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 123,67M Net Income (TTM) -38,63M
ROE -16,94% ROA -8,61%
Gross Margin 93,24% Operating Margin -43,83%
Net Margin -31,23% Free Cash Flow (TTM) -27,50M
ROIC -14,93% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,17 Current Ratio 6,12
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -24,82 P/B Ratio 4,11
P/S Ratio 7,75 PEG Ratio 0,64
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 958,61M Enterprise Value 867,92M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 123,67M 75,62M 0,0 0,0 0,0
Net Income -38,63M -72,70M -135,35M -108,50M -73,96M
EPS (Diluted) -0,46 -0,98 -2,63 -2,30 -1,59
Gross Profit 115,32M 67,50M -6,22M 0,0 0,0
Operating Income -54,21M -81,11M -143,31M -112,38M -72,88M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 448,66M 438,73M 303,76M 342,39M 366,33M
Total Liabilities 215,60M 215,80M 124,51M 70,98M 18,81M
Shareholders' Equity 233,06M 222,94M 179,25M 271,41M 347,52M
Total Debt 39,19M 42,72M 46,04M 47,00M 0,0
Cash & Equivalents 129,88M 224,25M 128,10M 54,91M 346,07M
Current Assets 393,19M 377,44M 236,21M 275,89M 348,67M
Current Liabilities 64,21M 156,95M 46,59M 25,57M 16,64M